The Minnesota Vikings locked up a three-time Pro Bowler with a fully guaranteed deal on Tuesday, and Vikings fans gave strong but mixed reviews. ESPN’s Adam Schefter reported that the Vikings gave ...

The Minnesota Vikings decided to release Aaron Jones last week, leaving a space on the roster at running back. Jordan Mason tops the depth chart, and after the first day of free agency, it looks like ...

As they prepared for the start of the legal tampering period across the NFL, the Vikings found a way to keep a key contributor in house. The announcement came on Monday morning that the Vikings have ...

MINNEAPOLIS — The Minnesota Vikings are making some roster moves ahead of the offseason free agency signing frenzy, which is about to begin soon in the NFL. The NFL's signing period does not ...

The Vikings’ scramble to create cap space won’t result in the release of veteran tight end T.J. Hockenson. NFL Media reports that the Vikings have restructured his contract, creating $5 million in ...

Viking Therapeutics aims to enter the billion-dollar weight loss drug market. The company is studying a candidate in a phase 3 trial. The weight loss drug market has been one key focus for investors ...

Is the Minnesota Vikings’ aging defense set for a youth revolution in the 2026 NFL Draft? Join Darren Campbell and Dave Stefano on Two Old Bloggers as they dissect Brian Flores’ strategy, linebacker ...

The Minnesota Vikings have announced the death of former cornerback Ronyell Whitaker at the age of 46. Whitaker's death on Sunday was confirmed by his family, who shared a statement paying tribute to ...

If the 2025 NFL season proved anything, it's that we should probably be more gracious with quarterbacks. Unfortunately, this is a grace that the Minnesota Vikings might not extend to second-year ...

The Minnesota Vikings are in a complete cap crunch to begin the 2026 offseason. They currently sit roughly around -$40 million in cap space for the coming year. There is no need to panic, though.

Shares of Viking Therapeutics (VKTX) continued to rise in the premarket on Thursday after the company provided encouraging updates on its experimental obesity therapy, VK2735, with its Q4 2025 results ...

Lian indicated the oral VK2735 program is expected to advance into Phase III for obesity, with initiation targeted for the third quarter of 2026. "We currently expect to initiate this program in the ...